Goldenwell Biotech, Inc.
GWLL
$3.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -33.33% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -33.33% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -33.33% | -- | |||
| SG&A Expenses | -23.89% | 25.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.89% | 25.70% | |||
| Operating Income | -90.32% | 90.40% | |||
| Income Before Tax | -53.85% | 84.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -53.85% | 84.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -53.85% | 84.88% | |||
| EBIT | -90.32% | 90.40% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 0.00% | 66.67% | |||
| Normalized Basic EPS | -- | 100.00% | |||
| EPS Diluted | 0.00% | 66.67% | |||
| Normalized Diluted EPS | -- | 100.00% | |||
| Average Basic Shares Outstanding | 0.00% | -2.59% | |||
| Average Diluted Shares Outstanding | 0.00% | -2.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||